Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04208152
Recruitment Status : Recruiting
First Posted : December 23, 2019
Last Update Posted : June 23, 2020
Sponsor:
Collaborators:
Quotient Sciences
Aptuit (Verona) Srl, an Evotec Company
Information provided by (Responsible Party):
MODAG GmbH

Brief Summary:
The purpose of this study is to determine the safety, tolerability and blood levels of orally administered anle138b in healthy subjects.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: anle138b Drug: Placebo Phase 1

Detailed Description:

This is a single-centre, study of double-blind, randomised, placebo-controlled single ascending doses (SAD) and multiple ascending doses (MAD) of anle138b in healthy subjects in study Parts 1 and 2. In study Part 3 the effect of food (FES) on the safety and PK of anle138b in healthy subjects is examined.

In the SAD cohorts, subjects will be randomly assigned to receive a single oral dose of active investigational medicinal product (IMP) or matching placebo in a sequential escalating manner with sufficient time planned between dose groups to allow interim review of the data.

In the MAD cohorts, subjects will be randomly assigned to receive oral doses of active IMP or matching placebo once daily (QD) for 7 days, in a sequential escalating manner with sufficient time planned between dose groups to allow interim review of the data.

In the FES, the effect of food on the safety and PK of anle138b is explored by administering a single dose of IMP after a high-fat breakfast. Subjects will be randomly assigned to one of 2 treatment sequence to receive anle138b in the fed or fasted state over 2 periods.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 92 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:

This study is double-blind. Treatment assignment will not be known to the subjects, the sponsor or the staff who are involved in the clinical evaluation of the subjects and the analysis of data. The randomisation schedule and disclosure envelopes will be generated by an unblinded statistician at Quotient Sciences.

The FES is an open label study which includes a randomized sequence of fasted and fed state.

Primary Purpose: Treatment
Official Title: A First-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of anle138b in Healthy Male and Female Subjects
Actual Study Start Date : December 6, 2019
Estimated Primary Completion Date : August 2020
Estimated Study Completion Date : October 2020


Arm Intervention/treatment
Active Comparator: anle138b
Dosage: 50 mg and higher Dosage form: capsule Frequency: once daily Duration: One day for SAD and seven days for MAD
Drug: anle138b
capsule containing excipient and anle138b

Placebo Comparator: placebo
Matching placebo Dosage form: capsule Frequency: once daily Duration: One day for SAD and seven days for MAD
Drug: Placebo
matching placebo capsule containing excipient




Primary Outcome Measures :
  1. Incidence of treatment-emergent adverse events in healthy volunteers with single ascending doses of anle138b (Part 1) [ Time Frame: Day 1 to day 30 post dose ]
    Adverse events (AEs)

  2. Incidence of treatment-emergent changes in clinical laboratory parameters in healthy volunteers with single ascending doses of anle138b (Part 1) [ Time Frame: Day 1 to day 7 post dose ]
    clinical laboratory tests including hematology and clinical chemistry including renal function tests, hepatic enzymes, electrolytes and creatine kinase

  3. Incidence of treatment-emergent changes in vital signs in healthy volunteers with single ascending doses of anle138b (Part 1) [ Time Frame: Day 1 to day 7 post dose ]
    Blood pressure, heart rate, oral temperature

  4. Incidence of treatment-emergent ECG changes in healthy volunteers with single ascending doses of anle138b (Part 1) [ Time Frame: Day 1 to day 7 post dose ]
    Electrocardiogram (ECG) parameters including QT interval corrected for heart rate using Fridericia's formula (QTcF)

  5. Incidence of treatment-emergent changes in physical examination in healthy volunteers with single ascending doses of anle138b (Part 1) [ Time Frame: Day 1 to day 7 post dose ]
    physical examination findings

  6. Incidence of treatment-emergent adverse events in healthy volunteers with multiple ascending doses of anle138b (Part 2) [ Time Frame: Day 1 to day 30 post dose ]
    Adverse events (AEs)

  7. Incidence of treatment-emergent changes in clinical laboratory parameters in healthy volunteers with multiple ascending doses of anle138b (Part 2) [ Time Frame: Day 1 to day 7 post dose ]
    clinical laboratory tests including hematology and clinical chemistry including renal function tests, hepatic enzymes, electrolytes and creatine kinase

  8. Incidence of treatment-emergent changes in vital signs in healthy volunteers with multiple ascending doses of anle138b (Part 2) [ Time Frame: Day 1 to day 7 post dose ]
    Blood pressure, heart rate, oral temperature

  9. Incidence of treatment-emergent ECG changes in healthy volunteers with multiple ascending doses of anle138b (Part 2) [ Time Frame: Day 1 to day 7 post dose ]
    Electrocardiogram (ECG) parameters including QT interval corrected for heart rate using Fridericia's formula (QTcF)

  10. Incidence of treatment-emergent changes in physical examination in healthy volunteers with multiple ascending doses of anle138b (Part 2) [ Time Frame: Day 1 to day 7 post dose ]
    physical examination findings

  11. Incidence of treatment-emergent adverse events in healthy volunteers with a single dose of anle138b both the fasted and fed state (Part 3) [ Time Frame: Day 1 to day 30 post dose. ]
    Adverse events (AEs)

  12. Incidence of treatment-emergent changes in clinical laboratory parameters in healthy volunteers with a single dose of anle138b both in the fasted and in the fed state (Part 3) [ Time Frame: Day 1 to day 7 post dose ]
    clinical laboratory tests including hematology and clinical chemistry including renal function tests, hepatic enzymes, electrolytes and creatine kinase

  13. Incidence of treatment-emergent changes in vital signs in healthy volunteers with a single dose of anle138b both in the fasted and in the fed state (Part 3) [ Time Frame: Day 1 to day 7 post dose ]
    Blood pressure, heart rate, oral temperature

  14. Incidence of treatment-emergent ECG changes in healthy volunteers with a single dose of anle138b both in the fasted and in the fed state (Part 3) [ Time Frame: Day 1 to day 7 post dose ]
    Electrocardiogram (ECG) parameters including QT interval corrected for heart rate using Fridericia's formula (QTcF)

  15. Incidence of treatment-emergent changes in physical examination in healthy volunteers with single ascending doses of anle138b both in the fasted and in the fed state (Part 3) [ Time Frame: Day 1 to day 7 post dose ]
    physical examination findings


Secondary Outcome Measures :
  1. Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state [ Time Frame: From dosing to 48 hours post dosing ]

    Time prior to the first measurable concentration of anle138b.

    Time prior to the first measurable concentration of anle138b.


  2. Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state [ Time Frame: From dosing to 48 hours post dosing ]
    Time of maximum observed concentration of anle138b.

  3. Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state [ Time Frame: From dosing to 48 hours post dosing ]
    Maximum observed concentration of anle138b.

  4. Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state [ Time Frame: From dosing to 48 hours post dosing ]
    Area under the curve from 0 time to 24 h post-dose of anle138b.

  5. Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state [ Time Frame: From dosing to 48 hours post dosing ]
    Area under the curve from 0 time to the last measurable concentration of anle138b.

  6. Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state [ Time Frame: From dosing to 48 hours post dosing ]
    Area under the curve from 0 time extrapolated to infinity of anle138b levels.

  7. Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state [ Time Frame: From dosing to 48 hours post dosing ]
    Percentage of area under the curve (0-inf) extrapolated beyond the last measurable concentration of anle138b.

  8. Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state [ Time Frame: From dosing to 48 hours post dosing ]
    Slope of the apparent elimination phase of anle138b.

  9. Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state [ Time Frame: From dosing to 48 hours post dosing ]
    Apparent elimination half-life of anle138b.

  10. Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state [ Time Frame: From dosing to 48 hours post dosing ]
    Mean residence time from 0 time to the last measurable concentration after extravascular administration of anle138b.

  11. Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state [ Time Frame: From dosing to 48 hours post dosing ]
    Mean residence time extrapolated to infinity after extravascular administration of anle138b.

  12. Oral pharmacokinetics (PK) of multiple (Part 2) ascending doses of anle138b in the fasted state [ Time Frame: Day 1 to day 9 ]
    Time of maximum observed concentration of anle138b

  13. Oral pharmacokinetics (PK) of multiple (Part 2) ascending doses of anle138b in the fasted state [ Time Frame: Day 1 to day 9 ]
    Maximum observed concentration of anle138b

  14. Oral pharmacokinetics (PK) of multiple (Part 2) ascending doses of anle138b in the fasted state [ Time Frame: Day 1 to day 9 ]
    Area under the curve over the dosing interval from time 0 to tau of anle138b

  15. Oral pharmacokinetics (PK) of multiple (Part 2) ascending doses of anle138b in the fasted state [ Time Frame: Day 7 to day 9 ]
    Slope of the apparent elimination phase (last dose only) of anle138b

  16. Oral pharmacokinetics (PK) of multiple (Part 2) ascending doses of anle138b in the fasted state [ Time Frame: Day 1 to day 9 ]
    Apparent elimination half-life (last dose only) of anle138b

  17. Oral pharmacokinetics (PK) of single (Part 1) and multiple (Part 2) ascending doses of anle138b in the fasted state [ Time Frame: Day 1 to day 9 ]
    Accumulation Ratio based on Cmax repeated dose /Cmax single dose of anle138b

  18. Oral pharmacokinetics (PK) of single (Part 1) and multiple (Part 2) ascending doses of anle138b in the fasted state [ Time Frame: Day 1 to day 9 ]
    Accumulation Ratio based on area under the curve (0 tau) repeated dose/AUC(0 tau) single dose of anle138b

  19. Oral pharmacokinetics (PK) (Part 3) for anle138b in the fed and fasted states. [ Time Frame: From dosing to 48 hours post dosing ]
    Maximum observed concentration of anle138b.

  20. Oral pharmacokinetics (PK) (Part 3) for anle138b in the fed and fasted states. [ Time Frame: From dosing to 48 hours post dosing ]
    Area under the curve from 0 time to the last measurable concentration of anle138b.

  21. Oral pharmacokinetics (PK) (Part 3) for anle138b in the fed and fasted states [ Time Frame: From dosing to 48 hours post dosing ]
    Area under the curve from 0 time extrapolated to infinity of anle138b levels.

  22. Oral pharmacokinetics (PK) (Part 3) for anle138b in the fed and fasted states [ Time Frame: From dosing to 48 hours post dosing ]
    Percentage of area under the curve (0-inf) extrapolated beyond the last measurable concentration of anle138b.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy males or women of no child bearing potential
  2. Age 18 to 55 years of age at the time of signing informed consent
  3. Body mass index (BMI) of 18.5 to 30.0 kg/m2 as measured at screening
  4. Must be willing and able to communicate and participate in the whole study
  5. Must provide written informed consent
  6. Must agree to adhere to the contraception requirements defined in Section 9.4
  7. In the investigator's opinion, subject is able to understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the protocol restrictions and requirements.

Exclusion Criteria:

  1. Subjects who have received any IMP in a clinical research study within the 90 days prior to Day 1.
  2. Subjects who are study site employees, or immediate family members of a study site or sponsor employee.
  3. Subjects who have previously been enrolled in this study. Subjects who have taken part in Part 1 are not permitted to take part in Part 2 or Part 3; subjects who have taken part in Part 2 are not permitted to take part in Part 3.
  4. History of any drug or alcohol abuse in the past 2 years.
  5. Regular alcohol consumption in males >21 units per week and females >14 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type).
  6. A confirmed positive alcohol breath test at screening or admission.
  7. Current smokers and those who have smoked within the last 12 months. A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission.
  8. Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months.
  9. Females of childbearing potential including those who are pregnant or lactating (all female subjects must have a negative urine pregnancy test at screening and serum pregnancy test on admission). A woman is considered of childbearing potential unless she is permanently sterile (hysterectomy, bilateral salpingectomy and bilateral oophorectomy) or is postmenopausal (had no menses for 12 months without an alternative medical cause and a serum follicle stimulating hormone concentration ≥40 IU/L).
  10. Subjects with pregnant or lactating partners.
  11. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening.
  12. Clinically significant abnormal clinical chemistry, haematology or urinalysis as judged by the investigator (laboratory parameters are listed in Appendix 1). Subjects with Gilbert's Syndrome are allowed. In addition the ALT and gamma glutamyl transferase (GGT) concentrations should not exceed the upper limit of normal (ULN) at screening and admission.
  13. Confirmed positive drugs of abuse test result (drugs of abuse tests are listed in Appendix 1) at screening or admission.
  14. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results
  15. Evidence of renal impairment at screening, as indicated by an estimated creatinine clearance of <70 mL/min using the Cockcroft-Gault equation.
  16. History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder, as judged by the investigator.
  17. Serious adverse reaction or serious hypersensitivity to any drug or the IMP excipients.
  18. Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active.
  19. Donation or loss of greater than 400 mL of blood within the previous 3 months.
  20. Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies (other than 4 g of paracetamol per day or HRT) in the 14 days before IMP administration (See Section 11.4). Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as determined by the PI.
  21. Failure to satisfy the investigator of fitness to participate for any other reason.
  22. In Part 3, subjects must be able to eat 90% of the US Food and Drug Administration (FDA)-approved high-fat breakfast, including bacon.
  23. Subjects with a previous history of difficulty in swallowing tablets or capsules, or an anticipated problem with swallowing a large number of capsules.
  24. Blood pressure (supine) at Screening or admission outside the range: 90 to 140 mmHg for subjects <45 years or 90 to 160 mmHg for subjects >45 years for systolic BP or 40 to 90 mmHg for diastolic BP; and pulse rate outside the range of 40 to 100 bpm, unless deemed not clinically significant by the investigator and the sponsor's medical monitor.
  25. Subjects with a history of cholecystectomy or gall stones.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04208152


Contacts
Layout table for location contacts
Contact: Johannes Levin, MD +49 6734 9622 ext 8000 levin@modag.net
Contact: Armin Giese, MD +49 6734 9622 ext 8000 giese@modag.net

Locations
Layout table for location information
United Kingdom
Quotient Sciences Recruiting
Nottingham, United Kingdom, NG11 6JS
Contact: Nand Singh, BSc, MD, DPM, MFPM    +44 (0)115 974 ext 9000    nand.singh@quotientsciences.com   
Contact: Sue Melbourne, DipNurs    +44 (0)115 931 ext 5120    sue.melbourne@quotientsciences.com   
Sponsors and Collaborators
MODAG GmbH
Quotient Sciences
Aptuit (Verona) Srl, an Evotec Company
Investigators
Layout table for investigator information
Principal Investigator: Nand Singh, BSc, MD, DPM, MFPM Quotient Sciences Mere Way Ruddington Fields Ruddington Nottingham NG11 6JS, UK
Additional Information:
Publications:

Layout table for additonal information
Responsible Party: MODAG GmbH
ClinicalTrials.gov Identifier: NCT04208152    
Other Study ID Numbers: anle138b-P1-01
2019-004218-33 ( EudraCT Number )
First Posted: December 23, 2019    Key Record Dates
Last Update Posted: June 23, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by MODAG GmbH:
anle138b
alpha-Synuclein
Oligomer modulator
Parkinson Disease
Multiple System Atrophy
Neurodegenerative diseases
Alzheimer Disease
Tauopathies
Amyloid